JPMorgan Chase & Co. Has $261,000 Position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

JPMorgan Chase & Co. grew its stake in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by 266.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 487,584 shares of the biopharmaceutical company’s stock after acquiring an additional 354,393 shares during the quarter. JPMorgan Chase & Co.’s holdings in Marinus Pharmaceuticals were worth $261,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of MRNS. World Investment Advisors LLC bought a new stake in Marinus Pharmaceuticals in the third quarter valued at approximately $104,000. Virtu Financial LLC acquired a new position in shares of Marinus Pharmaceuticals in the 4th quarter valued at $36,000. Deltec Asset Management LLC acquired a new position in shares of Marinus Pharmaceuticals in the 4th quarter valued at $107,000. Finally, Franklin Resources Inc. increased its position in shares of Marinus Pharmaceuticals by 34.9% in the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock valued at $8,483,000 after buying an additional 1,219,871 shares in the last quarter. 98.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on Marinus Pharmaceuticals in a research note on Sunday, April 27th. They issued a “sell” rating for the company. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Marinus Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $4.79.

Marinus Pharmaceuticals Price Performance

Shares of Marinus Pharmaceuticals stock opened at $0.55 on Friday. The firm has a market cap of $30.32 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. The stock’s 50-day moving average is $0.55 and its 200-day moving average is $0.51. Marinus Pharmaceuticals, Inc. has a one year low of $0.22 and a one year high of $1.97.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.